Background: Many countries consistently fail to achieve the target influenza vaccine coverage rate (VCR) of 75% for populations at risk of complications, recommended by the World Health Organization and European Council. We aimed to identify factors for achieving a high VCR in the scope of four benchmark countries with high influenza VCRs: Australia, Canada, UK and USA.

Methods: Publicly available evidence was first reviewed at a global level and then for each of the four countries. Semi-structured interviews were then conducted with stakeholders meeting predefined criteria. Descriptive cluster analyses were performed to identify key factors and pillars for establishing and maintaining high VCRs.

Results: No single factor led to a high VCR, and each benchmark country used a different combination of tailored approaches to achieve a high vaccine coverage. In each country, specific triggers were important to stimulate changes that led to improved vaccine coverage. A total of 42 key factors for a successful influenza vaccination programme were identified and clustered into five pillars: (1) Health Authority accountability and strengths of the influenza programme, (2) facilitated access to vaccination, (3) healthcare professional accountability and engagement, (4) awareness of the burden and severity of disease and (5) belief in influenza vaccination benefit. Each benchmark country has implemented multiple factors from each pillar.

Conclusion: A wide range of factors were identified from an evaluation of four high-performing benchmark countries, classified into five pillars, thus providing a basis for countries with lower VCRs to tailor their own particular solutions to improve their influenza VCR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789908PMC
http://dx.doi.org/10.7573/dic.2020-9-5DOI Listing

Publication Analysis

Top Keywords

influenza vaccination
12
vaccine coverage
12
improve influenza
8
high vcr
8
benchmark countries
8
key factors
8
benchmark country
8
influenza
7
factors
6
countries
6

Similar Publications

Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.

Sci Rep

December 2024

State Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.

Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine.

View Article and Find Full Text PDF

Long-term multi-systemic complications following SARS-CoV-2 Omicron and Delta infection in children: a retrospective cohort study.

Clin Microbiol Infect

December 2024

National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ministry of Health, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Objectives: Most studies on long-term sequelae of SARS-CoV-2-infection in children were conducted pre-Omicron and pre-dated vaccination rollout. We examined long-term risk of new-incident multi-systemic sequelae after SARS-CoV-2 Delta/Omicron infection in a multi-ethnic Asian pediatric population.

Methods: Retrospective cohort study of Singaporean children aged 1- 17 years infected during Delta/Omicron BA.

View Article and Find Full Text PDF

Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.

Vaccine

December 2024

Institute for Infectious Diseases and Endemic Diseases Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. Electronic address:

Introduction: The objective of our study was to estimate the influenza vaccine effectiveness for 2023/24 epidemic of co-circulating influenza A(H3N2) and B(Victoria) viruses in Beijing, China.

Methods: The surveillance-based study included all swabbed patients through influenza virological surveillance in Beijing, between October 2023 and March 2024. A Test-Negative Design(TND) was used to estimate influenza vaccine effectiveness(VE) against medically- attended laboratory-confirmed influenza in outpatient settings, also calculated the influenza vaccination rate(IVR).

View Article and Find Full Text PDF

Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.

Vaccine

December 2024

Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA 30303, USA. Electronic address:

The immune memory imprinted during an individual's initial influenza exposure (influenza imprinting) has long-lasting effects on the host's response to subsequent influenza infections and vaccinations. Here, we investigate how different influenza virus imprinting impacts the immune responses to subunit, inactivated virus, and protein-based nanoparticle vaccines in Balb/c mice. Our results indicated a phylogenetic distance-dependent effect of influenza imprinting on subunit hemagglutinin (HA) or formalin-inactivated (FI) virus vaccine immunizations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!